左炔诺孕酮宫内释放系统对子宫腺肌病的治疗价值评析(1)
[摘要] 目的 评估左炔诺孕酮宫内释放系统在子宫腺肌病治疗中的临床价值。方法 方便选取2013年2月—2016年11月该院100例子宫腺肌病患者，按照随机数字法分组，分析对照组50例常规治疗与实验组50例左炔诺孕酮宫内释放系统治疗的患者的不良反应发生率、治疗总有效率、性激素指标、临床指标、痛经积分。 结果 两组不良反应发生率、性激素指标差异无统计学意义(P>0.05)；实验组治疗总有效率较96.00%高于对照组(P<0.05)，痛经积分(6.35±1.42)分少于对照组(P<0.05)，血清CA125(24.3±5.2)kU/L、月经量PBAC评分(45.21±17.46)分、子宫体积(95.36+17.64)cm3等临床指标优于对照组，差异有统计学意义(P<0.05)。结论 左炔诺孕酮宫内释放系统治疗子宫腺肌病痛经积分低，临床指标能够显著改善，效果确切。
[关键词] 子宫腺肌病；左炔诺孕酮宫内释放系统；临床价值
[中图分类号] R711 [文献标识码] A [文章编号] 1674-0742(2017)05(b)-0135-03
[Abstract] Objective To evaluate the clinical value of levonorgestrel-releasing intrauterine system in treatment of adenomyosis. Methods 100 cases of adenomyosis patients treated in our hospital from February 2013 to November 2016 were convenient selected and randomly divided into two groups with 50 cases in each， the control group adopted the routine treatment， while the experimental group adopted the levonorgestrel-releasing intrauterine system treatment， and the incidence rate of adverse reactions， total treatment effective rate， sexy hormone index， clinical index and dysmenorrhea scores were compared between the two groups. Results The differences in the incidence rate of adverse reactions and sexy hormone between the two groups were not statistically significant(P>0.05)， and the total effective rate in the experimental group was 96.00%， which was higher than that in the control group(P<0.05)， and the dysmenorrhea score was (6.35±1.42)points， which was fewer than that in the control group(P<0.05)， and the serum CA125， menstrual flow PBAC score and uterus volume in the experimental group were respectively(24.3±5.2)kU/L， (45.21±17.46)points and (95.36±17.64)cm3， which were better than those in the control group， and the differences between groups were statistically significant(P<0.05). Conclusion The dysmenorrhea score of levonorgestrel-releasing intrauterine system in treatment of adenomyosis is low， which can obviously improve the clinical indexes and the effect is definite.
[Key words] Adenomyosis； Levonorgestrel-releasing intrauterine system； Clinical value
孕三烯酮等藥物治疗子宫腺肌病效果一般，而左炔诺孕酮宫内释放系统治疗效果确切。临床认为宫腔深度<9 cm为子宫腺肌病治疗的主要指征，同时目前临床少有子宫腺肌病应用左炔诺孕酮宫内释放系统的综合性疗效评估[1]。该研究方便选取100例2013年2月—2016年11月该院接受治疗的子宫腺肌病患者就此切入，探讨左炔诺孕酮宫内释放系统治疗对其痛经积分、不良反应发生率、临床指标、治疗总有效率与性激素指标的影响，结果所获颇丰，现报道如下。
1 资料与方法
1.1 一般资料
资料来源于方便选取该院收治的子宫腺肌病患者，选取例数为100例，按随机数字法将其分为实验组和对照组。其中，50例实验组患者中孕次0～6次，平均(2.3±0.5)次；产次0～3次，平均(1.1±0.2)次；年龄在34～59岁，平均为(50.4±4.2)岁。对照组50例患者年龄35～58岁，平均(50.6±4.4)岁；孕次0～5次，平均(2.1±0.6)次；产次0～2次，平均(1.2±0.3)次。实验组患者的基本资料与对照组差异无统计学意义(P>0.05)，可用于该次比较研究。, 百拇医药(宗威威)
[关键词] 子宫腺肌病；左炔诺孕酮宫内释放系统；临床价值
[中图分类号] R711 [文献标识码] A [文章编号] 1674-0742(2017)05(b)-0135-03
[Abstract] Objective To evaluate the clinical value of levonorgestrel-releasing intrauterine system in treatment of adenomyosis. Methods 100 cases of adenomyosis patients treated in our hospital from February 2013 to November 2016 were convenient selected and randomly divided into two groups with 50 cases in each， the control group adopted the routine treatment， while the experimental group adopted the levonorgestrel-releasing intrauterine system treatment， and the incidence rate of adverse reactions， total treatment effective rate， sexy hormone index， clinical index and dysmenorrhea scores were compared between the two groups. Results The differences in the incidence rate of adverse reactions and sexy hormone between the two groups were not statistically significant(P>0.05)， and the total effective rate in the experimental group was 96.00%， which was higher than that in the control group(P<0.05)， and the dysmenorrhea score was (6.35±1.42)points， which was fewer than that in the control group(P<0.05)， and the serum CA125， menstrual flow PBAC score and uterus volume in the experimental group were respectively(24.3±5.2)kU/L， (45.21±17.46)points and (95.36±17.64)cm3， which were better than those in the control group， and the differences between groups were statistically significant(P<0.05). Conclusion The dysmenorrhea score of levonorgestrel-releasing intrauterine system in treatment of adenomyosis is low， which can obviously improve the clinical indexes and the effect is definite.
[Key words] Adenomyosis； Levonorgestrel-releasing intrauterine system； Clinical value
孕三烯酮等藥物治疗子宫腺肌病效果一般，而左炔诺孕酮宫内释放系统治疗效果确切。临床认为宫腔深度<9 cm为子宫腺肌病治疗的主要指征，同时目前临床少有子宫腺肌病应用左炔诺孕酮宫内释放系统的综合性疗效评估[1]。该研究方便选取100例2013年2月—2016年11月该院接受治疗的子宫腺肌病患者就此切入，探讨左炔诺孕酮宫内释放系统治疗对其痛经积分、不良反应发生率、临床指标、治疗总有效率与性激素指标的影响，结果所获颇丰，现报道如下。
1 资料与方法
1.1 一般资料
资料来源于方便选取该院收治的子宫腺肌病患者，选取例数为100例，按随机数字法将其分为实验组和对照组。其中，50例实验组患者中孕次0～6次，平均(2.3±0.5)次；产次0～3次，平均(1.1±0.2)次；年龄在34～59岁，平均为(50.4±4.2)岁。对照组50例患者年龄35～58岁，平均(50.6±4.4)岁；孕次0～5次，平均(2.1±0.6)次；产次0～2次，平均(1.2±0.3)次。实验组患者的基本资料与对照组差异无统计学意义(P>0.05)，可用于该次比较研究。, 百拇医药(宗威威)